Skip to main content

Banzel FDA Approval History

FDA Approved: Yes (First approved November 14, 2008)
Brand name: Banzel
Generic name: rufinamide
Company: Eisai Medical Research Inc.
Treatment for: Lennox-Gastaut Syndrome

Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

Development timeline for Banzel

Feb 16, 2015Approval Eisai Receives Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients
Mar  4, 2011Approval FDA Approves Banzel (rufinamide) Oral Suspension, 40 mg/mL
Nov 17, 2008Approval FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
Nov 18, 2005Eisai Resubmits NDA for the Anti-epilepsy Drug Rufinamide
Sep 13, 2005Eisai Submits New Drug Application to the FDA for Anti-epileptic Drug Rufinamide

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.